Clinical trial
Type 1 Diabetes Intervention With Mazdutide for Efficacy, Safety and Cardiovascular Protection (The TIMES Trial Program-TIMES-EFFICACY & TIMES-CV
NCT07924553 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Type 1 Diabetes Intervention With Mazdutide for Efficacy, Safety and Cardiovascular Protection (The TIMES Trial Program-TIMES-EFFICACY & TIMES-CV
- Lead sponsor
- Peking University People's Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- June 1, 2029
- Enrollment
- 182 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
type 1 diabetes
Arms
As registered; 2 arms.
-
mazdutide group
Participants in the treatment group will receive mazdutide by subcutaneous injection once weekly. The dose will be escalated stepwise according to a pre-defined regimen from a safe starting dose to an effective maintenance dose (from 2 mg to 4 mg) over several weeks, with dose reduction permitted if needed.
-
placebo group
Participants in the control group will receive a placebo matched to mazdutide in appearance, packaging, and mode of administration, by subcutaneous injection once weekly.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Proportion of the participants achieving time in range (TIR)>70 and time below range (TBR)<4% (TIMES-EFFICACY)
The proportion of adult patients with T1D achieving the composite outcome of continuous glucose monitoring (CGM)-measured TIR \>70% and TBR \<4% at Week 16 in the mazdutide group versus the placebo group
-
Volume of non-calcified coronary artery plaque (TIMES-CV)
The absolute change in non-calcified coronary artery plaque volume in mm³ from baseline to Week 52, as measured by quantitative analysis of high-resolution coronary computed tomography angiography (CCTA)
Lead sponsor's other trials
Peking University People's Hospital, most recent start first.
+604 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 1) and phase, most recent start first.
+1,466 more trials See the condition page